ENSPRYNG CEMs can provide personal support to patients prescribed ENSPRYNG and their caregivers from day one—all at no cost. After receiving initial training from their healthcare provider, patients can access resources to reinforce what they’ve learned. CEMs do not perform injections.
CEMs can provide your patients:
Encourage your patients to schedule their first session with a CEM by calling 1-844-NSPRYNG.
*This program is intended primarily for patients prescribed ENSPRYNG who are in their first year of treatment. CEMs are Genentech employees and do not provide medical advice.
The video below about ENSPRYNG administration demonstrates how CEMs may help ENSPRYNG patients through additional education.
Voice-Over:
The subject of this video is Taking ENSPRYNG. ENSPRYNG is a prescription medicine used to treat neuromyelitis optica spectrum disorder, also known as NMOSD, in adults who are aquaporin-4, also known AQP4, antibody positive. It is not known if ENSPRYNG is safe and effective in children.
ENSPRYNG may cause serious side effects including infections, increased liver enzymes, and low neutrophil counts. All required vaccinations should be completed before starting ENSPRYNG. Do not take ENSPRYNG if you are allergic to satralizumab-mwge or any of the ingredients in ENSPRYNG, have an active hepatitis B infection or have active or untreated inactive (latent) TB.
Please see Important Safety Information at the end of this video. If you have any questions, please talk to your healthcare provider or refer to the ENSPRYNG Prescribing Information and Medication Guide.
This video features a Clinical Education Manager and a real person who is treating her NMOSD with ENSPRYNG.
DONNA:
Hello. My name is Donna. I was diagnosed with AQP4 positive NMOSD in 2014. So if you were diagnosed with NMOSD, I know what you’re going through as you look to learn more about this rare disease and consider your treatment options. This is one video in a series. I wish I would have had these videos to turn to when I was first diagnosed.
I’m now going to introduce you to Annette who is a Clinical Education Manager, also known as a CEM. Their job is to provide supplemental injection training to patients who have been prescribed ENSPRYNG and to caregivers when needed.
ANNETTE:
Thanks, Donna. Hello there, my name is Annette. I am a CEM with Genentech. I provide supplemental injection training and refresher supplemental injection training to patients and their caregivers, provided of course your doctor says you can self-inject with ENSPRYNG. I have guided many patients through this process. If you have questions or need a refresher, a CEM like me is there to support you during every step of this process.
ENSPRYNG is a monthly self-injectable treatment you can take on the go. You have a voice in how you manage your NMOSD treatment. If your healthcare provider determines it’s appropriate and after proper training, you or your caregiver have the ability to give it in the comfort of your own home or even while traveling, since ENSPRYNG can be stored at room temperature for a total of up to eight days, which don’t need to be eight days in a row.
ENSPRYNG is an injection that is given under the skin once a month via prefilled syringe, which gives the treatment flexibility and control over where you take it. Before and while taking ENSPRYNG, your healthcare provider may order tests and monitor you to ensure ENSPRYNG is still appropriate for you. Now that we’ve spoken about how ENSPRYNG is administered, let’s examine a chart that explains the dosing schedule for ENSPRYNG.
ENSPRYNG is a treatment that is given every four weeks after taking three starting doses in the first month of treatment. Here’s how the starting doses work. For the first four weeks, you are given one dose every two weeks. After that, you take one dose every four weeks. Doses are administered in a prefilled syringe that contain 120 mg of medicine. If a starting dose is missed, you should take it immediately, then maintain the two-week dosing interval from your new starting date until the first three doses are complete and then continue with ongoing doses every four weeks.
If an ongoing dose is missed, you should take it immediately. Wait the four-week interval from your new starting date and then continue with ongoing doses every four weeks.
Of course, you should always consult with your healthcare provider when it comes to administering the treatment they prescribed for you. As a CEM, I am also available to help answer questions you may have about self-injecting with ENSPRYNG.
One common question I get is how to store and handle ENSPRYNG which is the subject of our next slide. Follow these simple rules when storing and handling ENSPRYNG. Store ENSPRYNG in your refrigerator in its original box.
That protects it from light. If needed, unopened ENSPRYNG, can be removed from and returned to your refrigerator prior to administering it. Never freeze or shake the syringe. If for some reason the ENSPRYNG has to be stored at room temperature like when traveling, the total combined time out of the refrigerator should not be more than eight days at a temperature that is higher than 86 degrees Fahrenheit or 30 degrees Celsius.
I hope the information I shared with you today about taking ENSPRYNG was useful. Self-injection with ENSPRYNG can give you the flexibility to take it at a location that’s convenient for you, provided your healthcare provider determines it is appropriate and you have been trained on the proper technique.
Remember, if you are ever unsure and/or need to go over any of these steps again, you can always reach out to your CEM or even your Patient Navigator by calling 1-844-NSPRYNG. If they can’t answer a question, they can always point you in the right direction. Thank you for your time.
Now, let’s go back and get a closing thought from Donna, our Patient Ambassador.
DONNA:
Thanks, Annette. Living with NMOSD has brought certain challenges. Putting eye makeup on is not easy nor is playing pickleball. I lacked depth perception so I have a hard time figuring out where the ball is in relation to my paddle.
My sister and I laughed about it until we cried but we had fun trying. Being able to laugh at myself and find joy in everyday life has really made living with NMOSD bearable. After working with my doctor, I’m comfortable self-injecting with ENSPRYNG. For me, it’s empowering. I hope you found this video informative and helpful. Check out all the other videos in the series relating to ENSPRYNG at www.ENSPRYNG.com.
They are a valuable resource you can view any time. You can even watch them more than once as a refresher. Thanks for listening. Stay tuned for additional Important Safety Information.
This video, led by a Clinical Education Manager, provides information about injecting ENSPRYNG and is available in English and Spanish.
Get information or connect with others living with neuromyelitis optica spectrum disorder (NMOSD) through the following organizations†:
The Guthy-Jackson Charitable Foundation
The Siegel Rare Neuroimmune Association
†By selecting any of these links, you will be visiting a site not controlled by or affiliated with Genentech, Inc. Genentech is neither affiliated with nor endorses any of these organizations. We do not make any representation or guarantee as to the accuracy of the information contained on sites we do not own or control. These links are provided for informational purposes only.
Get answers to ENSPRYNG questions
ENSPRYNG [prescribing information]. South San Francisco, CA: Genentech, Inc. 2022.
ENSPRYNG [prescribing information]. South San Francisco, CA: Genentech, Inc. 2022.
Weinshenker B, Yeaman MR, de Seze J, et al. Long-term safety of satralizumab in adults with aquaporin-4-IgG-seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD). Presented at: the 75th Annual Meeting of the American Academy of Neurology; April 22-27, 2023; Boston, MA.
Weinshenker B, Yeaman MR, de Seze J, et al. Long-term safety of satralizumab in adults with aquaporin-4-IgG-seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD). Presented at: the 75th Annual Meeting of the American Academy of Neurology; April 22-27, 2023; Boston, MA.
Heo Y-A. Satralizumab: first approval. Drugs. 2020;80(14):1477-1482. https://doi.org/10.1007/s40265-020-01380-2
Heo Y-A. Satralizumab: first approval. Drugs. 2020;80(14):1477-1482. https://doi.org/10.1007/s40265-020-01380-2
Kawachi I, Lassmann H. Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2017;88(2):137-145. doi:10.1136/jnnp-2016-313300
Kawachi I, Lassmann H. Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2017;88(2):137-145. doi:10.1136/jnnp-2016-313300
Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology. 2003;60(5):848-853. doi:10.1212/01.wnl.0000049912.02954.2c
Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology. 2003;60(5):848-853. doi:10.1212/01.wnl.0000049912.02954.2c
Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82(6):474-481. doi:10.1212/wnl.0000000000000101
Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82(6):474-481. doi:10.1212/wnl.0000000000000101
Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. doi:10.1212/WNL.0000000000001729
Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. doi:10.1212/WNL.0000000000001729
Kessler RA, Mealy MA, Levy M. Treatment of neuromyelitis optica spectrum disorder: Acute, preventive, and symptomatic. Curr Treat Options Neurol. 2016;18(1):2. doi:10.1007/s11940-015-0387-9
Kessler RA, Mealy MA, Levy M. Treatment of neuromyelitis optica spectrum disorder: Acute, preventive, and symptomatic. Curr Treat Options Neurol. 2016;18(1):2. doi:10.1007/s11940-015-0387-9
Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176(2):149-164. doi:10.1111/cei.12271
Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176(2):149-164. doi:10.1111/cei.12271
Jeyalatha MV, Therese KL, Anand AR. An update on the laboratory diagnosis of neuromyelitis optica spectrum disorders. J Clin Neurol. 2022;18(2):152-162. doi:10.3988/jcn.2022.18.2.152
Jeyalatha MV, Therese KL, Anand AR. An update on the laboratory diagnosis of neuromyelitis optica spectrum disorders. J Clin Neurol. 2022;18(2):152-162. doi:10.3988/jcn.2022.18.2.152
Shah K, Maghsoudlou P. Enzyme-linked immunosorbent assay (ELISA): the basics. Br J Hosp Med (Lond). 2016;77(7):C98-C101. doi:10.12968/hmed.2016.77.7.C98
Shah K, Maghsoudlou P. Enzyme-linked immunosorbent assay (ELISA): the basics. Br J Hosp Med (Lond). 2016;77(7):C98-C101. doi:10.12968/hmed.2016.77.7.C98
Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402-412. doi:10.1016/S1474-4422(20)30078-8
Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402-412. doi:10.1016/S1474-4422(20)30078-8
Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, Hattori K. Engineering the variable region of therapeutic IgG antibodies. MAbs. 2011;3(3):243-252. doi:10.4161/mabs.3.3.15234
Igawa T, Tsunoda H, Kuramochi T, Sampei Z, Ishii S, Hattori K. Engineering the variable region of therapeutic IgG antibodies. MAbs. 2011;3(3):243-252. doi:10.4161/mabs.3.3.15234
Takeshita Y, Obermeier B, Cotleur AC, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2016;4(1):e311. doi:10.1212/NXI.0000000000000311
Takeshita Y, Obermeier B, Cotleur AC, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2016;4(1):e311. doi:10.1212/NXI.0000000000000311
Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013;19(12):1584-1596. doi:10.1038/nm.3407
Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013;19(12):1584-1596. doi:10.1038/nm.3407
Barros PO, Cassano T, Hygino J, et al. Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. Clin Exp Immunol. 2016;183(3):480-489. doi:10.1111/cei.12733
Barros PO, Cassano T, Hygino J, et al. Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. Clin Exp Immunol. 2016;183(3):480-489. doi:10.1111/cei.12733
Chugai Pharmaceutical Co, LTD. SMART-Ig. Accessed February 17, 2022. https://www.chugai-pharm.co.jp/english/ir/rd/technologies/files/eChugaiProprietaryTechnologies.pdf
Chugai Pharmaceutical Co, LTD. SMART-Ig. Accessed February 17, 2022. https://www.chugai-pharm.co.jp/english/ir/rd/technologies/files/eChugaiProprietaryTechnologies.pdf
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-815. doi:10.1016/S1474-4422(07)70216
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805-815. doi:10.1016/S1474-4422(07)70216
Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114-2124. doi:10.1056/NEJMoa1901747
Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114-2124. doi:10.1056/NEJMoa1901747
Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40(7):1830-1835. doi:10.1002/eji.201040391
Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40(7):1830-1835. doi:10.1002/eji.201040391
Uzawa A, Mori M, Taniguchi J, Masuda S, Muto M, Kuwabara S. Anti-high mobility group box 1 monoclonal antibody ameliorates experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2013;172(1):37-43. doi:10.1111/cei.12036
Uzawa A, Mori M, Taniguchi J, Masuda S, Muto M, Kuwabara S. Anti-high mobility group box 1 monoclonal antibody ameliorates experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2013;172(1):37-43. doi:10.1111/cei.12036
Rothhammer V, Quintana FJ. Control of autoimmune CNS inflammation by astrocytes. Semin Immunopathol. 2015;37(6):625-638. doi:10.1007/s00281-015-0515-3
Rothhammer V, Quintana FJ. Control of autoimmune CNS inflammation by astrocytes. Semin Immunopathol. 2015;37(6):625-638. doi:10.1007/s00281-015-0515-3
Data on file. Genentech, Inc. South San Francisco, CA.
Data on file. Genentech, Inc. South San Francisco, CA.
Kleiter I, Traboulsee A, Palace J, et al. Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2022;10(1):e200071. doi:10.1212/NXI.0000000000200071
Kleiter I, Traboulsee A, Palace J, et al. Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2022;10(1):e200071. doi:10.1212/NXI.0000000000200071
Efficacy and safety study of satralizumab (SA237) as monotherapy to treat participants with neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD). ClinicalTrials.gov identifier: NCT02073279. Updated February 22, 2022. Accessed November 16, 2022. https://clinicaltrials.gov/ct2/show/NCT02073279?id=NCT02073279
Efficacy and safety study of satralizumab (SA237) as monotherapy to treat participants with neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD). ClinicalTrials.gov identifier: NCT02073279. Updated February 22, 2022. Accessed November 16, 2022. https://clinicaltrials.gov/ct2/show/NCT02073279?id=NCT02073279
The information contained in this section of the site is intended for US healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.